We detected a wider range of (CAA) repeats than the Japanese cohort: 10, 11, 13, 14, 15, and 16 repeats, with 10 being the most common. In analogy with the Shikata study, we divided patients into groups according to genotype: (1) 10/10 repeats, (2) 10/11 or 11/11 repeats, and (3) 10/13 or 11/13 repeats. In addition, we had a fourth group of patients with more (CAA) repeats, that is, homozygous for 13 or heterozygous for 14, 15, or 16 repeats ( Figure 1A -B).
We could not confirm the Japanese finding of higher doses in individuals with 10/13 or 11/13 (CAA) repeats compared to patients with lower numbers of repeats ( Figure 1A ; groups 1, 2, and 3; P ϭ .616). However, when we included the fourth group in the analysis, we observed a difference of near nominal significance ( Figure 1A ; groups 1, 2, 3, and 4; P ϭ .064). When the fourth group was compared with all patients with fewer repeats, a significantly higher warfarin dose requirement was detected (Figure 1B ; groups 1-3 vs 4; P ϭ .011).
In our study, warfarin dose requirement tends to increase with the number of microsatellite repeats. This corresponds with the Japanese finding; however, in Swedes the effect is only apparent in patients with higher numbers of repeats. We have previously observed a GGCX polymorphism in intron 2 that increases warfarin dose requirement (P ϭ .036). 10 In univariate models, the GGCX microsatellite explains 3.5% of the variance in dose, while polymorphisms in GGCX, VKORC1, and CYP2C9 explain 3.3%, 29.9%, and 11.2%, respectively (Table 1) . 10 In a multiple model, the polymorphisms all show significant association to dose, but due to high linkage disequilibrium within the GGCX gene, no information is gained by adding the microsatellite to the model. Larger studies with different ethnicities will be needed to further elucidate the influence of GGCX variability on warfarin dosing. 
Role of VAD in the initial treatment of multiple myeloma
Rajkumar's obituary to VAD (vincristine-doxorubicin-dexamethasone) as initial therapy in multiple myeloma (MM) is premature. 1 Thalidomide-dexamethasone (Thal-Dex) is a promising regimen for upfront treatment of symptomatic myeloma prior to high-dose therapy and autologous stem cell transplantation (ASCT) with high response rates and convenience of oral administration, but has it done enough to usurp VAD and similar regimens?
We believe a change in clinical practice is mandated if Thal-Dex could demonstrate improved overall survival, reduced toxicity, or a significant reduction in cost without compromising clinical outcomes in comparison to VAD. However, we must be careful when drawing conclusions from surrogate outcomes such as response rate. While most studies have demonstrated the prognostic importance of achieving complete remission after ASCT, this has not been the case for the pre-ASCT response. 2, 3 In this regard, Cavo et al 4 demonstrated that Thal-Dex resulted in higher response rate with induction therapy compared to VAD but did not show improved overall survival. A recent large prospective randomized trial evaluating the role of intensive chemotherapy with or without thalidomide in the initial therapy of MM demonstrated higher complete remission and event-free survival with thalidomide, but similar overall survival for the 2 groups. 5 Few would argue that Thal-Dex is an innocuous regimen. Common adverse events of thalidomide include rash, sedation, neuropathy, deep venous thrombosis (DVT), and teratogenicity. 6 These risks balance with higher rates of granulocytopenia in VAD, thus the overall toxicity of Thal-Dex is not significantly different from VAD. 4 Finally, the cost savings of a purely oral regimen by avoiding hospitalization and central venous access are offset by the high cost of thalidomide, reflecting stringent monitoring and postmarketing surveillance. New agents such as lenalidomide or bortezomib also impose a heavy pharmaco-economic burden.
Thal-Dex remains a promising and useful initial regimen in MM prior to ASCT but falls well short of nailing the VAD coffin shut. It has not been demonstrated to improve overall survival or to reduce toxicity or costs. VAD remains useful and clinically relevant in the initial treatment of symptomatic MM. 
Response:

VAD and initial therapy for multiple myeloma
Lane and colleagues state that vincristine-doxorubicin-dexamethasone (VAD) remains important as initial therapy for myeloma since Thal/Dex has not shown superiority in terms of overall survival, toxicity, or cost. However, this argument overlooks many of the other reasons I stated why VAD is not a good option in this setting that have little to do with its relative efficacy compared to Thal/Dex. Two of these reasons are worth emphasizing again. First, in newly diagnosed myeloma, VAD has not been shown to be superior to dexamethasone alone using the same type of standards that Lane and colleagues argue are essential when comparing VAD and Thal/Dex. 1 Second, it is not wise to subject patients with newly diagnosed myeloma to the neurotoxicity of vincristine right up front when other alternatives are available. I share their concern about cost, toxicity, and lack of demonstrated overall survival
